The present study demonstrated that SR46349-B (10, but not 1-3, mg/kg), another putative APD and 5-HT2A/2C antagonist, but not M100907 (0.1 and 3 mg/ kg), alone increased mPFC DA release. Neither SR46349-B nor M100907 alone affected nucleus accumbens (NAC) DA release. SR46349-B (3 mg/kg) potentiated haloperidol-induced DA release in both regions, whereas M100907 (0.1 mg/kg) potentiated haloperidol (0.1 mg/kg)-induced mPFC DA release and inhibited it in the NAC.
The following is an excerpt with corrected text from the article's abstract:
The present study demonstrated that SR46349-B (10, but not 1-3, mg/kg), another putative APD and 5-HT2A/2C antagonist, but not M100907 (0.1 and 3 mg/ kg), alone increased mPFC DA release. Neither SR46349-B nor M100907 alone affected nucleus accumbens (NAC) DA release. SR46349-B (3 mg/kg) potentiated haloperidol-induced DA release in both regions, whereas M100907 (0.1 mg/kg) potentiated haloperidol (0.1 mg/kg)-induced mPFC DA release and inhibited it in the NAC.
The following is the corrected Conclusion section paragraph:
The 5-HT 2A receptor antagonists SR46349-B and M100907 can potentiate the ability of the typical APD haloperidol to increase DA release in the mPFC, via a 5-HT 1A receptor-dependent mechanism, as has been shown by the atypical APDs (Ichikawa et al. 2001a ). This combination may produce some of clinically relevant effects of atypical APDs. SR46349-B differs from M100907, a more selective 5-HT 2A receptor antagonist, probably due to its 5-HT 2C receptor antagonist properties. This difference may explain the ability of SR46349-B and M100907 (0.1, but not 3, mg/kg) to respectively potentiate and inhibit haloperidol-induced DA release in the NAC, via 5-HT 1A receptor-independent processes. 
